Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine

Neurological Sciences

Volumn 21, Issue 4, 2000, Pages 209-215

  Onofrj, M ^a   Thomas, A ^a   Bonanni, L ^a   Iacono, D ^a   Gambi, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Clozapine; Leucopenia; Olanzapine; Parkinson's disease

Indexed keywords

CLOZAPINE; OLANZAPINE;

AGED; ARTICLE; CASE REPORT; DISEASE EXACERBATION; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; PARKINSON DISEASE; PARKINSONISM;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALLUCINATIONS; HUMANS; LEUKOPENIA; MALE; PARKINSON DISEASE; PIRENZEPINE; PSYCHOTIC DISORDERS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0034486079     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720070078     Document Type: Article

References (50)

1. Factor SA, Friedman JH (1997) The emerging role of clozapine in the treatment of movement disorders. Mov Disord 4:483-496
2. Friedman JH (1991) The management of levodopa psychoses. Clin Neuropharmacol 14:283-295
3. Melamed E, Friedberg G, Zoldan J (1999) Psychosis: impact on the patient and the family. Neurology 52[Suppl 3]:S14-16
4. The Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340(10):757-763
5. Ruggieri S, De Pandis MF, Bonamarini A, Vacca L, Stocchi F (1997) Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol 20(3):204-209
6. Friedman JH, Factor SA (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15:210-211
7. Bennett JP, Landow ER, Schuh LA (1993) Suppression of dyskinesia in advanced Parkinson's disease. II Increasing daily clozapine doses suppress dyskinesias and improve parkinsonian symptoms. Neurology 43:1551-1555
8. Arevalo GJ, Gershanik OS (1993) Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 8:349-54
9. Bonuccelli U, Cervavolo R, Salvetti S, D'Avino C, Del Dotto P, Rossi G, Murri L (1997) Clozapine in Parkinson's disease tremor. Effects of acute and chronical administration. Neurology 49(6):1587-1590
10. Hinze-Selch D, Mullington J, Orth A, Lauer CJ, Pollächer T (1997) Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry 42:260-266
11. Tschen AC, Rieder MJ, Oyewumi LK, Freman DJ (1999) The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther 65(5):526-532
12. Swartz JR, Ananth J, Smith MW, Burgoyne KS, Gadasally R, Arai Y (1999) Treatment after clozapine-induced granulocytopenia in 3 patients. J Clin Psychiatry 60(2):119-121
13. Ministero della Sanità (1999) Prescrizione dei farmaci per indicazioni diverse da quelle autorizzate. Bollettino Italiano Farmacovigilanza VI(1-2):35-42
14. -(1997) Physicians' desk reference, 51st edn. Medical Economics, Montvale, pp 2377-2380
15. Avorn J, Bohn RL, Mogun H et al (1995) Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 99:48-54
16. Fleischacker WW, Unterweger B, Kane JM, Hinterhuber H (1990) The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 81:3-5
17. Danielczyk W (1973) Die Behandlung von akinetischen Krisen. Med Welt 24:1278
18. Philbrick KL, Rummans TA (1994) Malignant catatonia. Neuropsychiatry Clin Neurosci 6:1-13
19. McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB International Workshop. Neurology 47(5):1113-1124
20. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
21. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM (1996) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 47:1085-1087
22. Lambert T (1998) Olanzapine after clozapine: the rare case of prolungation of granulocytopaenia Aust N Z J Psychiatry 32(4):591-592
23. Onofrj M, Thomas A (2000) One further case of pancytopenia induced by olanzapine in a Parkinson's disease patient. Eur Neurol (in press)
24. Meissner W, Montplaisir T, Kupsch A, Trottenberg T, Lempert T (1999) Reversible leucopenia related to olanzapine. Mov Disord 14(5):872-889
25. Friedman JH, Goldstein S, Jaques C (1998) Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol 21(5):285-288
26. Graham JM, Sussman JD, Ford KS, Sagar HJ (1998) Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry 65(5):774-777
27. Molho ES, Factor SA (1999) Worsening of motor features of parkinsonism with olanzapine. Mov Disord 14(6):1014-1016
28. Gibb WRG (1988) Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgraduate Med J 64:345-351
29. Hughes AJ, Daniel SE, Blankson S et al (1993) A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50:140-148
30. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG (2000) Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology 54:1616-1624
31. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo, Fowler C, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenningen GK (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163(1):94-98
32. Fahn S, Elton R, Members of UPDRS Development Committee (1987) In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease, vol 2. Macmillan Health Care Information, Florham Park, pp 153-164, pp 293-304
33. Folstein NF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for clinician. J Psychiatry Res 12:189-198
34. Wechsler D (1981) WAIS-R manual. Wechsler adult intelligence scale revised. Psychological, New York
35. Hathaway SR, McKinley JC (1951) The Minnesota multiphasic personality inventory manual. Psychological, New York
36. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308-2314
37. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW (1986) Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 9:293-308
38. Moore NA, Coligaro DO, Wong DT et al (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drug 2:281-293
39. Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Comm Chem Pathol Pharmacol 77:87-93
40. Jimenez-Jimenez FJ, Tallon-Baranco A, Orti-Pareja M et al (1998) Olanzapine can worsen parkinsonism. Neurology 50:1183-1184
41. Friedman JH, Goldstein S (1998) Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 50:1195-1196
42. Weiner WJ, Minagar A, Shulman LM (1998) Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease Mov Disord 13:862
43. Stover NP, Juncos JL (1999) Olanzapine treatment of parkinsonian patients with psychosis. Neurology 55[Suppl 2]:A215 (abstract)
44. Fernandez HH, Cannon MC, Friedmann JH, Abbott BP (2000) Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 15(3):579-586
45. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson's disease, diagnosis and treatment. Neurology 52 [Suppl 3]:S10-S13
46. Factor SA, Molho ES, Podskalny GD, Brown D (1995) Parkinson's disease: drug induced psychiatric states. Adv Neurol 65:115-138
47. Uitti RJ, Tanner CM, Rajut AH, Goetz CG, Klawan HL, Thiessen B (1989) Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12:375-383
48. Fernadez HH, Durso Raymon (1998) Clozapine for dopaminergic-induced paraphilias in Parkinson's disease. Mov Disord 13(3):597-621
49. Secchi GP, Tanda F, Mutani R (1984) Fatal hyperpyrexia after withdrawal of levodopa. Neurology 34:249-251
50. Simpson DM, Davis GC (1984) Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 141:796-797